{"abstract":"The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the March 23, 2026, expiration date.","action":"Notice; renewal of Federal advisory committee.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2024/06/07/2024-12528.html","cfr_references":[],"citation":"89 FR 48653","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":"Authority for the Obstetrics, Reproductive and Urologic Drugs Advisory Committee will expire on March 23, 2026, unless the Commissioner formally determines that renewal is in the public interest.","disposition_notes":null,"docket_ids":["Docket No. FDA-2022-N-0335"],"dockets":[{"supporting_documents":[],"agency_name":"FDA","documents":[{"comment_count":0,"comment_start_date":"2024-06-07","updated_at":"2024-09-03T17:04:22.361-04:00","comment_url":"https://www.regulations.gov/commenton/FDA-2022-N-0335-0002","allow_late_comments":false,"id":"FDA-2022-N-0335-0002","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":0,"id":"FDA-2022-N-0335","title":"Advisory Committee; Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Renewal"}],"document_number":"2024-12528","effective_on":null,"end_page":48654,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2024/06/07/2024-12528.xml","html_url":"https://www.federalregister.gov/documents/2024/06/07/2024-12528/advisory-committee-obstetrics-reproductive-and-urologic-drugs-advisory-renewal","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2024-12528?publication_date=2024-06-07","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2024-06-07/2024-12528/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":153,"last_updated":"2026-10-24 04:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-06-07/pdf/2024-12528.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-12528.pdf?1717677940","publication_date":"2024-06-07","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2024/06/07/2024-12528.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[],"comments_count":0,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2022-N-0335","supporting_documents_count":0,"docket_id":"FDA-2022-N-0335","document_id":"FDA-2022-N-0335-0002","regulation_id_number":null,"title":"Advisory Committee; Obstetrics, Reproductive and Urologic Drugs Advisory Committee; Renewal","checked_regulationsdotgov_at":"2024-06-08T14:00:14Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":48653,"subtype":null,"title":"Advisory Committee; Obstetrics, Reproductive and Urologic Drugs Advisory; Renewal","toc_doc":"Obstetrics, Reproductive and Urologic Drugs Advisory Committee","toc_subject":"Charter Amendments, Establishments, Renewals and Terminations:\n","topics":[],"type":"Notice","volume":89}